Are you the publisher? Claim or contact us about this channel

Embed this content in your HTML


Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog

Channel Description:

Visit One News Page for Australia news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Australia news headlines.

older | 1 | .... | 1441 | 1442 | (Page 1443) | 1444 | 1445 | .... | 1460 | newer

    0 0

    Auckland, New Zealand, Dec 27, 2018 / 05:45 am (CNA).- When your business runs out of money and you need a miracle, whom do you call? The Catholic Church, apparently.

    Warwick Jordan is a New Zealander, the owner of the second-hand bookstore “Hard to Find Bookshop” - and not Catholic.  

    This summer, Jordan found himself strapped for cash. The building in which he kept his bookshop had been sold and bought by new owners, who were now asking for commercial rent, which was out of his budget.

    He tried everything to raise the funds, including an online crowdsourcing page on Give a Little. Even though he was able to raise $27,000, that still wasn’t enough.

    That’s when he decided to ask for a miracle.

    “We'd bought books off Catholic priests and had bought a massive stash from St. Benedict's at one stage. I wrote to the Bishop and said 'I need a miracle. I understand the Catholic Church specializes in miracles - can you pull one out of the bag for me?'” Jordan told *New Zealand news site Newsroom*.

    “Bishop Pat (Dunn (of Auckland)) wrote back and said he'd put it before the property board, but a couple of weeks went by without hearing and I thought we were screwed. We were looking at how we would wind up,” he added.

    But his plea hadn’t fallen on deaf ears.

    Bishop Dunn called him back and offered him a former home of Australia’s only saint, St. Mary Mackillop, who was a teacher dedicated to education.

    Also known as St. Mary of the Cross, MacKillop founded the Congregation of the Sisters of St. Joseph of the Sacred Heart. She focused particularly on the education of poor children and established some of the first Catholic schools in Australia.

    She began the order’s work with a school in a stable the small town of Penola, Australia in 1866. Before her death many more educational institutions were established in isolated “bush” areas where hardship was common.

    Today, the “Josephite” sisters are present across Australia and New Zealand, and have extended their ministry to Ireland, Peru, East Timor, Scotland and Brazil.

    “With its high ceilings, plaster domes, huge windows allowing light to flood in, and polished floor boards, it had all the character he was looking for. It was in poor condition but had the rent to match,” Alexia Russell said of the home in her article for Newsroom.

    After getting a loan to cover the rest of the costs, Jordan re-opened his shop June 15. He makes appropriate use of the space, too. The theology section is housed in what once was the chapel, along with extra information about St. Mary Mackillop.

    “We wanted to honour her - we're her guests, I think it's appropriate. Her thing was about education and supporting knowledge to all people. She was a strong person who sorted people out ... I love people with strong characters. Up to a point,” Jordan told Newsroom.

    In the age of Amazon and charity bookshops, Jordan realizes that even the miraculous relocation isn’t enough to guarantee he won’t have financial troubles in the future.

    “I’m the captain of the Titanic,” he said. “But I couldn't imagine doing anything else.”

    This article was originally published on CNA June 27, 2018. Reported by CNA 1 day ago.

    0 0

    Toyota could add Corolla TRD to challenge Golf GTI, Veloster N Toyota has a new Corolla on its hands, one that doesn't look like something your grandma would drive—and the car could be destined to receive some performance upgrades to back its racy looks. Australia's Car Sales reported Thursday that a Corolla GR hot hatch is being developed to challenge models from Hyundai's new N performance division... Reported by MotorAuthority 18 hours ago.

    0 0

    Airlines are offering some flight deals to entice you to book that spring break or summer vacation now

      Reported by 18 hours ago.

    0 0

    Hanley Wood, the premier information, media, event, and strategic marketing services company serving the residential, commercial design, and construction industries is pleased to announce the winners of the CONCRETE SURFACES annual Polished Concrete Awards program.

    WASHINGTON, DC (PRWEB) December 27, 2018

    Hanley Wood, the premier information, media, event, and strategic marketing services company serving the residential, commercial design, and construction industries is pleased to announce the winners of the CONCRETE SURFACES annual Polished Concrete Awards program.
    “Regardless of scale, these projects were impressively executed,” says CONCRETE SURFACES Editor Stephanie Johnston. “Each contractor’s painstaking attention to the process is what makes these floors truly shine.”

    New Construction: B:Hive (Business Hive) at Smales Farm Office Park
    46,284 square feet
    Polished Concrete Ltd.
    Auckland, New Zealand

    Repair/Rehabilitation: Ann Arbor Office Building (Ann Arbor, Mich.)
    3,800 square feet
    Anderson Concrete
    Brooklyn, Mich.

    New Construction: Northwood Middle School (Spokane, Wash.)
    30,000 square feet
    Cameron-Reilly LLC
    Spokane Valley, Wash.

    Repair/Rehabilitation: Jackson Area Career Center (Jackson, Mich.)
    3,900 square feet
    Anderson Concrete
    Brooklyn, Mich.

    Romulus Business Center (Romulus, Mich)
    500,000 square feet
    Syncon Inc.
    Livonia, Mich.

    LDS Pacific Church History Museum (Hamilton, New Zealand)
    2,853 square feet
    Polished Concrete Ltd.
    Auckland, New Zealand

    Defense Information School at Fort Meade (Fort Meade, Md.)
    4,000 square feet
    Industrial Caulk and Seal Inc.
    Delta, Pa.

    New Construction: Seamless White (Perth, Western Australia)
    4,240 square feet
    DS Grinding Pty Ltd.
    Clarkson, Western Australia

    Repair/Rehabilitation: Liberty at Laurel Hill (Lorton, Va.)
    98,000 square feet
    Industrial Caulk and Seal Inc.
    Delta, Pa.

    Jack's Point Clubhouse & Restaurant (Queenstown, New Zealand)
    5,000 square feet
    Polished Concrete Ltd.
    Auckland, New Zealand

    Northwood Middle School (Spokane, Wash.)
    30,000 square feet
    Cameron-Reilly LLC
    Spokane Valley, Wash.

    Descriptions and photos of all entries are available online at

    Winning projects will be published in the January 2019 issue of CONCRETE SURFACES, a supplement of CONCRETE CONSTRUCTION magazine published for contractors who specialize in polishing, coating, treating, stamping, staining, repairing, and rehabilitating concrete. CONCRETE SURFACES is a World of Concrete official publication.

    About Hanley Wood
    Hanley Wood is the premier company serving the information, media, and marketing needs of the residential, commercial design and construction industry. Utilizing the largest analytics and editorially driven Construction Industry Database - powered by Metrostudy - the company provides business intelligence and data-driven services. The company produces award-winning media, high-profile executive events, and strategic marketing solutions. To learn more, visit Reported by PRWeb 18 hours ago.

    0 0

    A record-shattering heat wave continued to scorch Australia on Thursday as temperatures soared above 120 degrees in some spots.

      Reported by 15 hours ago.

    0 0

    HOBART, Australia (AP) — Wild Oats XI won the 74th Sydney to Hobart yacht race on Friday, claiming line honors for the ninth time. The Mark Richards-skipped super maxi crossed the line in Hobart shortly after 8 a.m. local time (2100 GMT Thursday) after taking the lead from defending line honors champion Comanche before sunrise. […] Reported by Seattle Times 15 hours ago.

    0 0

    Australians will be cranking up the pedestal fans, as extreme heatwave conditions sear across most of the country.

    Temperatures have soared above average across much of the continent, peaking at 49.1°C (120.38°F) in the town of Marble Bar in Western Australia, according to the Bureau of Meteorology (BOM).

    Much of Australia is experiencing a #heatwave#Temperatures peaked at 49°C today in Marble Bar in the W. High temperatures will continue over the next few days away from the S coast. Some places could reach December records, eg Canberra, which currently stands at 39.2 degrees

    — Met Office (@metoffice) December 27, 2018

    More about Australia, Global Warming, Extreme Weather, Climate Change, and Heatwave Reported by Mashable 11 hours ago.

    0 0

    AFC Asian Cup 2019: Group B Preview - Australia, Jordan, Syria and Palestine Goal takes a look at the Group B contenders of the 24-team event which gets underway on January 5... Reported by 8 hours ago.

    0 0

    Revolut, the UK's $1.7 billion star fintech, has big dreams as it takes on the American market· London's Revolut was founded only three years ago, but it already has 3 million customers and is aiming for 100 million customers in the next five years.
    · The challenger bank is set to hit the US market in early 2019, and it says 75,000 people are already on the waiting list.
    · "We want to one of the largest financial services companies in the world," CEO Nikolay Storonsky said.

    An app-based banking alternative in the UK valued at $1.7 billion has plans to grow even bigger. Just three years old, it's hitting the US early next year to continue its rapid expansion.

    Revolut, founded in 2015 by developer Vlad Yatsenko and former Lehman Brothers and Credit Suisse trader Nikolay Storonsky, already has 3.2 million customers, and the company boasts that it has long waiting lists outside Europe. Dubbed "the Amazon of banking," Revolut raised $250 million earlier this year and has reportedly lured a potential $500 million investment from Japan's SoftBank.

    The London-based company allows users to spend money worldwide in 150 currencies at a real-time exchange rate, with no fees, through a debit card. CEO Storonsky outlined his goal of seeing the bank reach 100 million customers in the next five years and break into North American and Pacific markets in the coming months.

    "We want to be one of the largest financial services companies in the world and continue our expansion," Storonsky said in an interview with Business Insider. "That's my dream."

    The US market has long been on Revolut's list for expansion, he said, but with significantly higher barriers to entry than Europe, progress has been slow. The company had originally planned to expand into the US by the end of 2018 but is now expecting a rollout early next year, in late March or early April.

    Among the hurdles: US regulations require domestically issued debit cards to use a different interbank messaging system — basically how banks send and receive information such as money transfers — from the rest of the world. And US debit cards must have at least two networks to be compliant. Rather than partner with a US provider, Storonsky said Revolut opted to build its own US-based processor.

    The company will decide soon which bank to partner with in the US as part of its offering.

    "Regulation is key — in the UK, it's very quick," said Storonsky, who holds a masters in economics from the New Economic School in Moscow. "But as you become a big organization, regulators pay much more attention, which can slow things down."

    In addition to the US, Revolut plans to expand to Canada, Australia, New Zealand, Hong Kong, Singapore, and Japan in 2019. The company recently announced it had received a Remittance License from the Monetary Authority of Singapore, as well as Stored Value Facility approval, and also noted it had been fully authorized by Japan's JFSA boosting its expansion plans. 

    *Read more:* UK fintechs claim Brexit could lead to a 'lost generation' of London businesses

    Storonsky declined to comment on any potential SoftBank investment and was coy on the prospect of future funding.

    "It depends how much investors are willing to invest," he said. "We're open to new investors, but them having a good reputation is important."

    Previous Series C funding was led by DST Global, the investment vehicle of Russian billionaire Yuri Milner, who was an early investor of Facebook, Twitter, and Spotify, among others. Existing Revolut investors Index Ventures and Ribbit Capital also took part in the financing.

    So far, Revolut's success has been built on its low-fee, multicurrency platform. But Storonsky sees cryptocurrencies, already on offer via Revolut, as an enduring part of the company's future. Cryptocurrencies have plunged in 2018, with their combined market cap now at $130 billion, down from a high of $800 billion in January, according to research site CoinMarketCap.

    "Banks are still very risk-averse of crypto, institutional funds as well," Storonsky said. "As a result, Wall Street is not really interested — there is no demand from institutional clients."

    On the product side, Revolut offers customers three options: a free account, a premium account, or the recently introduced metal account. The latter provides users with unlimited exchange in 24 fiat currencies, as well as five major cryptocurrencies: bitcoin cash, bitcoin core, ethereum, litecoin, and ripple.

    Storonsky said that Revolut has managed to sidestep the Brexit snags that have impacted a large number of other UK fintechs. The firm has applied for a European banking license from the Bank of Lithuania and is considering an application for an electronic-money license in Luxembourg as part of its plans to reduce any Brexit-related issues.

    *SEE ALSO: Revolut is planning a metal 'Platinum' card that will give people 1% cash back in cryptocurrencies*

    Join the conversation about this story »

    NOW WATCH: The legendary economist who predicted the housing crisis says the US will win the trade war Reported by Business Insider 2 hours ago.

    0 0

    India's first innings lead of 292 is the highest they have ever achieved in a Test in Australia, points out Rajneesh Gupta. Reported by 2 hours ago.

    0 0

    Pat Cummins, on Friday, said Australian batsmen need to learn a lot from India captain Virat Kohli and Cheteshwar Pujara Reported by 2 hours ago.

    0 0
  • 12/28/18--03:11: Mesoblast Corporate Review
  • NEW YORK and MELBOURNE, Australia, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine industry. Two commercial products have already been approved and marketed by the Company’s licensees JCR Pharmaceuticals Co, Ltd. in Japan and Takeda Pharmaceutical Company in Europe. Mesoblast has one product candidate which has successfully completed Phase 3 and with near-term commercial potential in the United States (U.S.), another product candidate having achieved clinical outcomes in line with the U.S. Food and Drug Administration (FDA) guidance for a registrable clinical indication for market authorization, and two additional Phase 3 assets with blockbuster potential.Mesoblast has recently entered into a strategic cardiovascular partnership for China with Tasly Pharmaceutical Group, China’s leading cardiovascular company, and is in advanced and active discussions with a number of potential global commercialization partners to maximize the value proposition of each of our blockbuster cell therapy candidates. 

    Mesoblast’s royalty income and milestone payments from licensees continues to grow, the Company has sufficient cash to achieve key commercial milestones, and access to additional non-dilutive sources of capital from strategic financial institutions whose extensive due diligence provides further third party validation of the strength of the product portfolio and patent estate.

    Below is a summary of the current status of the product portfolio and the developments expected to take place in 2019.

    *Substantial Commercialization Opportunities*

    Mesoblast’s proprietary immunoselected and culture-expanded allogeneic mesenchymal precursor cells (MPCs) are a homogeneous, well characterized, and highly reproducible cell population that are manufactured to industrial scale for commercial purposes. They express an array of surface receptors that bind pro-inflammatory cytokines and, when placed into a pro-inflammatory microenvironment, release factors that switch off production of these cytokines. Their immunomodulatory mechanism of action makes MPCs uniquely suited to target resistant diseases where inflammation plays a central role.

    *Acute Graft Versus Host Disease*, *a Life-threatening Inflammatory Condition*
    In Q1 2019, the Company plans to initiate the FDA process of filing a Biologics License Application (BLA) for market authorization of remestemcel-L in the U.S., where there are no approved therapies for steroid-refractory acute Graft Versus Host Disease (aGVHD). Underpinning Mesoblast’s confidence in the U.S. market access plan is the Japan experience, where Mesoblast’s licensee, JCR Pharmaceuticals, markets TEMCELL^®1 HS Inj. for children and adults with aGVHD.

    Importantly, TEMCELL has achieved substantial adoption rates in just over 2.5 years, helping inform the view of the product value proposition potential in the U.S. market. With an experienced commercial leadership in place, Mesoblast is establishing a focused sales team that will target the principal U.S. transplant centers, and will be in place on FDA approval to ensure a successful product launch.

    *Inflammation Due to Left Ventricular Assist Device Implants in End-stage Heart Failure Patients* 
    In the first half of 2019, Mesoblast plans to meet with the FDA to discuss a potential approval pathway following the clinically meaningful outcomes of reduction in major gastrointestinal (GI) bleeding and related hospitalizations seen in the U.S. National Institutes of Health (NIH)-sponsored Phase 2 trial of MPC-150-IM (Revascor) in patients with end-stage heart failure and a left ventricular assist device (LVAD). This potentially life-threatening complication is the most common non-surgical complication in LVAD recipients and occurs in up to 40% of patients.

    In the 159-patient trial, a single intra-cardiac injection of Revascor resulted in a 76% reduction in major GI bleeding episodes and in 65% reduction in associated hospitalization events. Reduction in GI bleeding and associated hospitalizations were the basis of the Regenerative Medicine Advanced Therapy (RMAT) designation granted in December 2017 by the FDA for use of Revascor in LVAD patients based on concordant data from the earlier 30-patient Pilot Trial. In a subsequent meeting in 2018, the FDA advised Mesoblast that reduction in major GI bleeding in LVAD patients is considered a clinically meaningful outcome by the FDA and an acceptable endpoint for product approval.  

    In end-stage heart failure, where intra-cardiac inflammation is greatest, putting a foreign object (the LVAD) in contact with the failing left ventricle results in further activation of intra-cardiac inflammation, which exacerbates pre-existing vascular dysfunction in the peripheral organs. The GI blood vessels respond to vascular dysfunction and reduced flow by generation of abnormal thin-walled, leaky capillaries (angiodysplasia). These pre-dispose LVAD patients to massive and life-threatening GI bleeding. 

    Mesoblast believes that reduction in major GI bleeding episodes by Revascor is due to reduction in intra-cardiac inflammation and the associated vascular dysfunction in peripheral organs, including the GI vessels. If this is correct, this will have significant read-through to the Phase 3 trial in patients with class II/III heart failure where intra-cardiac inflammation and peripheral vascular dysfunction are thought to directly result in recurrent hospitalizations and terminal cardiac events.

    *Phase 3 Trial in Moderate to Advanced Chronic Heart Failure**, a Progressive Disease of Cardiac Inflammation*
    Mesoblast expects to complete patient recruitment in the Phase 3 trial evaluating Revascor in patients with moderate-to-severe advanced chronic heart failure very shortly. In the U.S. alone, there are more than 1.3 million patients with New York Heart Association (NYHA) class III chronic heart failure who have high rates of morbidity and mortality despite existing therapies. The major unmet medical need in these patients represents a potential multi-billion dollar market opportunity for Mesoblast.

    The primary endpoint for this Phase 3 trial is the ability of Revascor to reduce recurrent non-fatal heart failure-related major adverse cardiac events (HF-MACE) in patients with left ventricular dysfunction. The key secondary endpoint is to delay or prevent terminal cardiac events (TCEs), defined as death, left ventricular assist device implantation, or heart transplant.

    It is important to note that in the Phase 2 LVAD trial patients with ischemic cause of their heart failure showed the greatest benefits after being treated with Revascor and these patients closely resemble the majority of patients enrolled in the ongoing Phase 3 trial of patients with moderate to advanced heart failure. If the mechanism of action by which Revascor improved GI bleeding is indeed reduction of intra-cardiac inflammation and reversal of impaired functioning of blood vessels (endothelial dysfunction), a known primary cause of morbidity, exercise intolerance, and mortality in heart failure and a proven mechanism of action for many drugs in early heart failure, one would expect to see a reduction in HF-MACE and mortality in this Phase 3 trial. 

    *Chronic Low Back Pain Due to Inflammatory Degenerative Disc Disease* 
    In the U.S., the declared opioid public health emergency and significant associated mortality has brought additional attention to Mesoblast’s product candidate, MPC-06-ID, with the Phase 3 trial completing enrollment of 404 patients in 2018. More than half of the prescriptions for opioids are for people seeking relief from chronic low back pain. There is a desperate need for a therapy that can offer both a durable reduction in pain and improvement in function without the risk of opioid addiction.

    Underpinning Mesoblast’s confidence that MPC-06-ID may meet this medical need are the Phase 2 data outcomes that supported the ongoing Phase 3 trial which showed that a single intra-discal injection of MPC-06-ID alleviated pain and improved function for up to three years in patients whose symptoms were not adequately treated with current standard of care therapies.

    The patient population suffering from chronic low back pain due to intervertebral disease is estimated at more than 3.2 million patients in the U.S. alone. Mesoblast’s objective is to select and secure the ideal strategic partner to maximize the value creation potential inherent in MPC-06-ID.

    *Upcoming Milestones*

    *Remestemcel-L for Acute Graft Versus Host Disease
    *     - FDA meetings and BLA filing (Early CY19)

    *Revascor for End-Stage Heart Failure
    *     - Meet with FDA to discuss the clinically meaningful GI bleeding Phase 2 trial data for potential BLA filing (1H CY19)

    *Phase 3 Events-driven Trial in Advanced Heart Failure
    *     - Complete recruitment (Q4 CY18/Q1 CY19)
         - Cardiovascular partner Tasly Pharmaceuticals to meet with National Medical Products Administration to discuss the regulatory approval pathway in China (Q1 CY19)
         - Establish global partnership 

    *MPC-06-ID for Chronic Low Back Pain
    *     - Establish global partnership

    *About Mesoblast
    *Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary technology platform to establish a broad portfolio of late-stage product candidates with three product candidates in Phase 3 trials – acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. Through a proprietary process, Mesoblast selects rare mesenchymal lineage precursor and stem cells from the bone marrow of healthy adults and creates master cell banks, which can be industrially expanded to produce thousands of doses from each donor that meet stringent release criteria, have lot to lot consistency, and can be used off-the-shelf without the need for tissue matching. Mesoblast has facilities in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).

    1. TEMCELL^® HS Inj. is the registered trademark of JCR Pharmaceuticals Co. Ltd.

    *Forward-Looking Statements
    *This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblast’s preclinical and clinical studies; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

    For further information, please contact:

    Julie Meldrum
    Corporate Communications
    T: +61 3 9639 6036

    Schond Greenway
    Investor Relations
    T: +1 212 880 2060
    E: Reported by GlobeNewswire 2 hours ago.

    0 0

    Dec 28 (OPTA) - Scoreboard at close of play of match 10 between Sydney Sixers and Melbourne Stars on Thursday at Sydney, Australia Melbourne Stars win by 5 wickets Sydney Sixers 1st innings Jack Edwards st Peter Handscomb b Adam Zampa 4 Joe Denly c Dwayne Bravo b Glenn Maxwell 14 Daniel Hughes b Jackson Coleman 20 Moises Henriques lbw Sandeep Lamichhane 9 Jordan Silk Not Out Reported by Reuters India 1 hour ago.

    0 0

    Tim Paine has been making headlines for his creative sledging behind the wickets in the ongoing Test series between India and Australia. Reported by DNA 1 hour ago.

    0 0

    JinkoSolar Together with Schneider Electric Donated a 55kW Off-grid Solar Project in Egypt SHANGHAI, Dec. 28, 2018 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or "Company") (NYSE code: JKS), a reputable solar module manufacturer in the world, today announced its partnership with Schneider Electric to donate a 55kW off-grid solar project in Abu Redis, South Sinai, Egypt.

    The remote village called ABU GHURAQD is located about 30 km away from Abu Redis, which comprises of 35 families, a mosque, a school, a small medical center and three farms. The total connected power load includes 15kW residential load and two 25kW irrigation pumps. Prior to completion of the project, the only electricity source of the village was three 30 kW diesel generators supplying the village with electricity for merely 8 hours per day, which could not sufficiently meet the power load demand. Additionally, the noise and air pollution caused by diesel generators were another issue for local residents.

    The project has been successfully completed and involved several challenges including governmental approvals and permissions, material security and transportation, as well as operation and maintenance responsibility. The completed off-grid solar power system covers power load for the village for 20 hours per day, significantly improving the life quality of the local residents. Reduced operation time of diesel generators is also helpful for environment protection.

    "We're pleased to form a strong partnership with Schneider Electric to deliver this meaningful project. At JinkoSolar, we believe that access to energy is a fundamental human right, and this project is directly in line with that," said Dany Qian, VP of JinkoSolar. "In addition to the contribution to the effective and efficient operation of renewable energy facilities worldwide by providing products and solutions that are highly reliable and offer a good return on investment, JinkoSolar will strive to serve as a responsible corporate citizen with CSR initiatives centered on environmental awareness and clean energy accessibility to all." 

    *About JinkoSolar Holding Co., Ltd.*

    JinkoSolar (NYSE: JKS) is a world-renowned solar module manufacturer. JinkoSolar has over 12,000 employees across its 6 productions facilities globally. The company distributes its solar products and sells its solutions and services to a diversified international utility, commercial and residential customer base in more than 80 countries worldwide. JinkoSolar has built a vertically integrated solar product value chain, with an integrated annual capacity of 9.2 GW for silicon ingots and wafers, 6.5 GW for solar cells, and 10 GW for solar modules, as of September 30, 2018.               

    JinkoSolar has over 12,000 employees across its 6 productions facilities globally, 16 oversea subsidiaries in Japan (2), Singapore, India, Turkey, Germany, Italy, Switzerland, United States, Canada, Mexico, Brazil, Chile, Australia, South Africa and United Arab Emirates, and global sales teams in United Kingdom, Bulgaria, Greece, Romania, Jordan, Saudi Arabia, South Africa, Egypt, Morocco, Ghana, Kenya, Costa Rica, Colombia, Panama and Argentina.

    To find out more, please see: 

    *Safe Harbor Statement*

    This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will,""expects,""anticipates,""future,""intends, "plans,""believes,""estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in JinkoSolar's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    *For investor and media inquiries, please contact: *

    In China:
    Mr. Sebastian Liu
    JinkoSolar Holding Co., Ltd.
    Tel: +86 21-5183-3056

    View original content:

    Related Links : Reported by PR Newswire Asia 1 hour ago.

    0 0

    *Efore Plc                                                                       **Stock Exchange Release 28 December 2018, at 13:15*
    * *

    *Final result of Efore Plc’s rights issue – the EUR 11 million rights issue was oversubscribed*


    Efore Plc’s (“*Efore*” or the “*Company*”) rights issue (the “*Offering*”) has been successfully completed and as a result of the Offering the Company will raise the targeted gross proceeds of approximately EUR 11 million. The 106.0 percent oversubscription, as indicated by the preliminary result published on 20 December 2018, has increased by 1.9 percentage points in the final result. The current CEO Jorma Wiitakorpi’s and the new CEO Vesa Leino’s comments on the final results: “We are both extremely pleased with the final result. This creates an excellent basis for the implementation of Efore’s updated strategy.”

    A total of 394,606,136 shares were subscribed for in the Offering  which ended on 19 December 2018, representing approximately 107.9 percent of the 365,863,897 shares offered (the “*Offer Shares*”). A total of 321,594,721 Offer Shares were subscribed for pursuant to the subscription rights in the primary subscription, representing approximately 87.9 percent of the Offer Shares. A total of 66,011,415 shares were subscribed for without subscription rights in the secondary subscription, representing approximately 18.0 percent of all the Offer Shares. The Board of Directors of Efore has today approved all subscriptions made in the Offering pursuant to the subscription rights and decided to approve the secondary subscriptions made by Efore’s shareholders and other investors in accordance with the terms and conditions of the Offering.

    Members of the Board of Directors of the Company, CEO Jorma Wiitakorpi and CFO Vesa Leino had each separately given their pre-commitments to subscribe for Offer Shares that are left over after the primary and secondary subscriptions, representing a total of 7,000,000 Offer Shares. Because the Offering was oversubscribed, Offer Shares could not be allocated to the Board of Directors, CEO and CFO based on their pre-commitments to subscribe for shares and thus their subscription commitments were not executed. 

    A total of 44,269,176 Offer Shares were allocated in the secondary subscription in proportion with subscription rights exercised in accordance with the terms and conditions of the Offering.

    The subscription price was EUR 0.03 per Offer Share, and Efore raised gross proceeds of approximately EUR 11.0 million through the Offering. In accordance with the terms and conditions of the Offering, some of the subscription prices were paid, as resolved by the Board of Directors, by setting off against loans and accrued interest relating to the financing arrangement announced 10 April 2018. As a result of the Offering, the total number of shares in Efore will increase to 421,636,788 shares. The Offer Shares will entitle their holders to full shareholder rights in Efore after the Offer Shares have been registered with the Finnish Trade Register and in Efore’s shareholder register, on or about 28 December 2018.

    Trading in the interim shares representing the Offer Shares subscribed for in the primary subscription commenced on Nasdaq Helsinki Ltd (the “*Helsinki Stock Exchange*”) on 20 December 2018. Interim shares will be combined with Efore’s existing class of shares when the Offer Shares have been registered with the Finnish Trade Register, on or about 28 December 2018. Trading in the Offer Shares on the official list of Helsinki Stock Exchange together with Efore’s existing shares will commence on or about 2 January 2019.

    Evli Bank Plc is the lead manager of the Offering. The Company’s legal advisor is Castrén & Snellman Attorneys Ltd.

    Helsinki, 28 December 2018

    Efore Plc

    Board of Directors

    Additional information:

    Jorma Wiitakorpi, CEO, Efore Plc, tel. +358 40 175 8510
    Vesa Leino, CFO, Efore Plc, tel. +358 40 759 8956


    Nasdaq Helsinki

    Key media


    The information contained in this document is not for publication or distribution, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or the United States. The issue, subscription and sale of securities are subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions.

    The information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published by the Company.

    This document is not an offer for the sale of securities in the United States, and the securities referred to herein cannot be offered or sold in the United States, unless they have been registered or are exempt from registration in accordance with the US Securities Act of 1933 (as amended) and the regulations and orders issued thereunder. There is no intention to register any portion of the offering in the United States or to conduct a public offering of securities in the United States.

    The Company has not authorised any offer to the public of securities in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area other than Finland and which has implemented the Prospectus Directive (each, a ‘Relevant Member State’), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive. In this paragraph, the expression ‘offer securities to the public’ means communication by any means presenting sufficient information on the terms of the offer and the securities to be offered, so as to enable an investor to decide to use, purchase or subscribe for these securities, as the expression may vary due to the implementation measures taken in the Member State. The expression ‘Prospectus Directive’ refers to Directive 2003/71/EC (as amended, including the 2010 Amending Directive, to the extent that it has been implemented in the Relevant Member State), and it includes all relevant implementation measures in the Relevant Member State, and the expression ‘2010 Amending Directive’ refers to Directive 2010/73/EC.

    The information contained herein shall not constitute a public offering of shares in the United Kingdom. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ‘Order’) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as ‘relevant persons’). Any investment activity to which this document relates will be only available to, and will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

    The information contained in this document is for background purposes only and does not purport to be full or complete. No reliance may or should be placed by any person for any purposes whatsoever on the information contained in this document or on its completeness, accuracy or fairness. The information in this document is subject to change.

    This document contains certain forward-looking statements. These forward-looking statements involve risks and uncertainties that could significantly affect expected results and are based on certain key assumptions. Many factors could cause actual results to differ materially from those projected or implied in any forward-looking statements. Due to these uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this document. The Company disclaims any obligation to update any forward-looking statements contained in this document, except as required pursuant to applicable law. Reported by GlobeNewswire 2 hours ago.

    0 0

    Jasprit Bumrah said his experience of getting reverse swing on slower pitches in First-Class cricket helped him get the best out of a docile MCG track after his six-wicket haul put India in command in the third Test in Melbourne. Reported by DNA 1 hour ago.

    0 0
  • 12/28/18--04:20: Big Bash League Scoreboard
  • Dec 28 (OPTA) - Scoreboard at close of play of match 11 between Hobart Hurricanes and Sydney Thunder on Friday at Hobart, Australia Hobart Hurricanes win by 7 wickets Sydney Thunder 1st innings Jos Buttler c&b Jofra Archer 89 Shane Watson lbw Riley Meredith 20 Callum Ferguson b Clive Rose 15 Joe Root c Riley Meredith b Clive Rose 17 Jason Sangha c Clive Rose b James Faulkner 7 Daniel Sams c Jo Reported by Reuters India 32 minutes ago.

    0 0

    Tom Rogic Celtic vs Australia row set to rumble on as Hoops star unlikely to play against Oman The midfielder has been forced to miss the game against Rangers at Ibrox despite the fact he's set to be rested against Oman. Reported by Daily Record 1 hour ago.

    0 0

    Bundled out for a paltry 151 in the first innings, pacer Pat Cummins on Friday said Australian batsmen need to learn a lot from India captain Virat Kohli and Cheteshwar Pujara on how to pace their knocks on this MCG pitch. Reported by DNA 1 hour ago.

older | 1 | .... | 1441 | 1442 | (Page 1443) | 1444 | 1445 | .... | 1460 | newer